Anaplastic Plasmacytoma - 139 Studies Found
| Completed |
: Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma : Multiple Myeloma and Plasma Cell Neoplasm : 2006-06-08 : Drug: fluphenazine hydrochloride |
| Completed |
: Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma : Multiple Myeloma and Plasma Cell Neoplasm : 2006-06-07 :
|
| Completed |
: Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma : Multiple Myeloma and Plasma Cell Neoplasm : 2006-04-24 :
|
| Completed |
: Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma :
: 2006-04-24 :
|
| Completed |
: Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma : Multiple Myeloma and Plasma Cell Neoplasm : 2006-04-19 :
|
| Completed |
: Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma : Multiple Myeloma and Plasma Cell Neoplasm : 2006-04-11 :
|
| Completed |
: Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma : Multiple Myeloma and Plasma Cell Neoplasm : 2006-03-21 :
|
| Completed |
: Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant : Multiple Myeloma and Plasma Cell Neoplasm : 2006-02-06 : Drug: bortezomib Dose of Bortezomib* Level 1: 1.3 mg/m2 on Day 1, 4, 8, 11 - Every 21 days; Level 2: 1.3 |
| Terminated |
: Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders : Multiple Myeloma and Plasma Cell Neoplasm : 2005-11-22 :
|
| Completed |
: Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma : Multiple Myeloma and Plasma Cell Neoplasm : 2005-11-22 :
|